CERTAINTY by Certara 2024 | Teaser
Transcript: The Certara community and interdisciplinary industry experts and scientists from model and form drug…
CertaraFebruary 29, 2024
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— February 29, 2024-- Certara, Inc. (Nasdaq: CERT), a…
CertaraFebruary 29, 2024
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator
The Simcyp Simulator is a software platform for population physiologically-based pharmacokinetic (PBPK) modeling and simulation.…
CertaraFebruary 23, 2024
RAPS: How Will Generative AI Take Your Regulatory and Medical Writing Program to the Next Level?
Drug developers face increasing pressures to accelerate the drug development process, including reducing submission timelines.…
CertaraFebruary 22, 2024
How to Navigate the FDA Landscape for an Orphan Drug
Rare diseases are a public health priority. FDA has launched several programs and a final…
CertaraFebruary 21, 2024
Dose Optimization Considerations for Targeted Radiation Therapies
The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio…
CertaraFebruary 16, 2024
The interaction of core modules as a basis for elucidating network behavior determining Parkinson’s disease pathogenesis
It is well-established that misfolded alpha-synuclein (alpha-syn) is a histopathological marker of Parkinson's disease. Given…
CertaraFebruary 14, 2024
